ClinicalTrials.gg
CompletedNCT05681273Updated Jun 15, 2023

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

A Phase 1 interventional study of Chiglitazar and Empagliflozin in T2DM, sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin,Atorvastatin and Valsartan in healthy subjects.

02

Conditions studied

  • T2DM
03

In context

Lead sponsor

Chipscreen Biosciences, Ltd. is the lead sponsor of 42 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects between the ages of 18 and 45 years, inclusive;
  • 19.0≤≤26.0 kg/m2. Weight of male ≥50 kg and Weight of female ≥ 45 kg.

Exclusion criteria

Exclusion Criteria:

  • History of allergy or atopic allergic disease, or allergy to the study drug;
  • Previous surgery may affect drug absorption, distribution, metabolism and excretion; or have suffered from gastrointestinal, liver and kidney diseases that can affect drug absorption or metabolism in the past 6 months;
  • History of tuberculosis;
  • Frequent infection history in the past year, or serious infections leading to hospitalization within 3 months before administration;
  • untreated diarrhea, or diarrhea within 7 days before administration;
  • Any drugs, vitamin products or herbal medicine used within 1 month before administration;
  • History of drug abuse;
  • Participated in clinical trial within 3 months before administration;
  • Blood donation or massive blood loss within 3 months before the first administration;
  • Pregnant or lactating women;
  • Regular drinking history; or took any alcoholic products within 48 hours before administration; or positive alcohol test;
  • Regular smoking history within 3 months before administration or cannot quit smoking during the trial;
  • \<80 mL/min;
  • Abnormal results of laboratory examination,vital signs, 12 lead , physical examination and chest X-ray;
  • Systolic blood pressure\<90 or ≥ 140 mmHg, diastolic blood pressure\<60 or ≥ 90 mmHg;
  • Other situations that are not suitable for participate the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Group A

    D1: Oral single dose of Empagliflozin 10 mg; D5\~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Empagliflozin 10 mg and Chiglitazar 48 mg.

    Drug: Chiglitazar · Drug: Empagliflozin

  • Experimental
    Group B

    D1: Oral single dose of Atorvastatin 20 mg; D5\~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Atorvastatin 20 mg and Chiglitazar 48 mg.

    Drug: Chiglitazar · Drug: Atorvastatin

  • Experimental
    Group C

    D1: Oral single dose of Valsartan 160 mg; D5\~9: Oral multiple doses of Chiglitazar 48 mg; D10: Oral single dose of Valsartan 160 mg and Chiglitazar 48 mg.

    Drug: Chiglitazar · Drug: Valsartan

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum plasma concentration

    Time frame: up to 72 hours

  2. AUC0-t and AUC0-inf

    Area under of the curve (AUC0-t and AUC0-inf)

    Time frame: up to 72 hours

07

Study locations

1 site
  • Zhongshan hospital
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Mar 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2022
First posted
Jan 12, 2023
StartActual
Feb 17, 2023
Primary completionActual
Mar 21, 2023
CompletionActual
Mar 21, 2023
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05681273
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
Feb 17, 2023
Primary completion
Mar 21, 2023
Completion
Mar 21, 2023
Last update
Jun 15, 2023

Study contacts

Hongrong Xu
principal investigator · Shanghai Zhongshan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Chiglitazar · Empagliflozin · Atorvastatin · Valsartan

Start the discussion